Theratechnologies presents combined Phase 3 results

Theratechnologies (TSX:TH)  presented pooled results from both its phase 3 clinical trials evaluating tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy at a conference in Germany. Treatments with two milligrams of tesamorelin daily for 26 weeks resulted in a significant decrease in visceral adipose tissue, no clinically significant changes in [...]

Theratechnologies’ new drug application for tesamorelin to be reviewed by FDA advisory committee

An advisory committee of the FDA will review Theratechnologies’ new drug application for tesamorelin to treat excess abdominal fat in HIV patients with lipodystrophy. “We view the solicitation of additional viewpoints from various external groups as positive and, over the next few months, we will work together with the FDA to prepare for the meeting,” [...]